Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Stomach Neoplasms 16Lung Neoplasms 9Neoplasm Metastasis 5Neoplasms 4Adenocarcinoma 4Colonic Neoplasms 3Carcinoma, Hepatocellular 3Thymoma 2Rectal Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × Ramucirumab × Clear all
NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Eli Lilly and Company

Phase 2 Active not recruiting
309 enrolled 22 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡